Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

istituto biochimico italiano giovanni lorenzini s.p.a. - propofol - propofol

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

hospira italia s.r.l. - propofol - propofol

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

esseti farmaceutici s.r.l. - metilprednisolone - metilprednisolone

Italia - italiano - Ministero della Salute

zoetis italia s.r.l. - isoflurano - isoflurano - 100 ml - isoflurane

Unione Europea - italiano - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - reiezione del trapianto - immunosoppressori - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

baxter ag - desfluranum - liquido per la produzione di vapore per inalazione - desfluranum 100 %, pro vitro. - inhalationsnarkotikum - synthetika

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

dr. reddy's s.r.l. - sugammadex - sugammadex

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

b. braun melsungen ag - propofol - propofol

Italia - italiano - myHealthbox

basilea medical ltd. - ceftezolo - polvere per concentrato per soluzione per infusione - ogni flaconcino contiene 500 mg di ceftobiprolo. dopo la ricostituzione, ogni ml di concentrato contiene 50 mg di ceftobiprolo - altre cefalosporine - trattamento delle infezioni: polmonite acquisita in ospedale (hap) esclusa la polmonite associata a ventilazione meccanica (ventilator-associated pneumonia, vap), polmonite acquisita in comunità (cap)

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

aspen pharma trading limited - analoghi della purina - analoghi della purina